Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
暂无分享,去创建一个
J. Reis-Filho | L. Norton | B. Weigelt | E. Brogi | M. Robson | T. Traina | S. Patil | H. Wen | P. Selenica | C. D. Dos Anjos | R. Hoda | Katia Ventura | Anne Grabenstetter
[1] Amy M. Sitapati,et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] E. Winer,et al. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer , 2020, Clinical Cancer Research.
[3] M. Kurosumi,et al. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer , 2019, Scientific Reports.
[4] Akintunde Akinleye,et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.
[5] Xue Qin,et al. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer , 2019, OncoTargets and therapy.
[6] V. Reuter,et al. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology , 2019, The American journal of surgical pathology.
[7] G. Curigliano,et al. Recent advances in triple negative breast cancer: the immunotherapy era , 2019, BMC Medicine.
[8] F. Bertucci,et al. Genomic characterization of metastatic breast cancers , 2019, Nature.
[9] Z. Zeng,et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.
[10] Quirine F. Manson,et al. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases , 2018, Clinical & Experimental Metastasis.
[11] L. Pusztai,et al. Immunological differences between primary and metastatic breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.
[13] B. Taylor,et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.
[14] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[15] F. Wang,et al. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia , 2018, Cancer.
[16] A. Schneeweiss,et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[19] Steven J. M. Jones,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.
[20] C. Sotiriou,et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Ahmet Zehir,et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. , 2017, JCO precision oncology.
[22] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[23] Minghui Zhang,et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis , 2017, Oncotarget.
[24] S. Tyldesley,et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed , 2017, Breast Cancer Research and Treatment.
[25] Carsten Denkert,et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.
[26] J. Joo,et al. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. , 2016, Clinical breast cancer.
[27] Toby C. Cornish,et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.
[28] Zhongyu Yuan,et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer , 2015, Oncotarget.
[29] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[30] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] L. Pusztai,et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Cancer Immunology Research.
[32] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[33] F. Gao,et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.
[34] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[35] P. Sharma,et al. PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.
[36] F. André,et al. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[38] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[39] C. Parise,et al. Variation in breast cancer subtypes with age and race/ethnicity. , 2008, Critical reviews in oncology/hematology.
[40] A. Tsodikov,et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004 , 2008, Cancer.
[41] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[42] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[43] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[44] E. Cameron,et al. The Runx genes: lineage-specific oncogenes and tumor suppressors , 2004, Oncogene.
[45] K. Shigesada,et al. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11 , 2004, Oncogene.
[46] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] W T McGivney,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[48] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[49] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[50] E B Cox,et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.
[51] P. Fasching,et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.
[52] L. Sarian,et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. , 2016, Human pathology.
[53] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[54] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.